{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:26:30Z","timestamp":1740147990534,"version":"3.37.3"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100011541","name":"Division of Cancer Epidemiology and Genetics, National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA072720"],"award-info":[{"award-number":["P30CA072720"]}],"id":[{"id":"10.13039\/100011541","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Urol Rep"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s11934-020-01021-x","type":"journal-article","created":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T01:03:03Z","timestamp":1609894983000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["From Diagnosis to Therapy\u2014PET Imaging for Pheochromocytomas and Paragangliomas"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6475-670X","authenticated-orcid":false,"given":"Hiren V.","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5818-973X","authenticated-orcid":false,"given":"Arnav","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7233-6361","authenticated-orcid":false,"given":"Murray D.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5262-6353","authenticated-orcid":false,"given":"Toni","family":"Beninato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9208-0789","authenticated-orcid":false,"given":"Amanda M.","family":"Laird","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3991-0696","authenticated-orcid":false,"given":"Eric A.","family":"Singer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,6]]},"reference":[{"issue":"6","key":"1021_CR1","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1210\/jc.2014-1498","volume":"99","author":"JW Lenders","year":"2014","unstructured":"Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(6):1915\u201342. https:\/\/doi.org\/10.1210\/jc.2014-1498.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1021_CR2","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1530\/eje.0.1500681","volume":"150","author":"JP Baguet","year":"2004","unstructured":"Baguet JP, Hammer L, Mazzuco TL, Chabre O, Mallion JM, Sturm N, et al. Circumstances of discovery of phaeochromocytoma: a retrospective study of 41 consecutive patients. Eur J Endocrinol. 2004;150(5):681\u20136.","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"1021_CR3","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1530\/EJE-09-0384","volume":"161","author":"R Kopetschke","year":"2009","unstructured":"Kopetschke R, Slisko M, Kilisli A, Tuschy U, Wallaschofski H, Fassnacht M, et al. Frequent incidental discovery of phaeochromocytoma: data from a German cohort of 201 phaeochromocytoma. Eur J Endocrinol. 2009;161(2):355\u201361. https:\/\/doi.org\/10.1530\/EJE-09-0384.","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"1021_CR4","doi-asserted-by":"publisher","first-page":"12","DOI":"10.4103\/0974-7796.62919","volume":"2","author":"J Wen","year":"2010","unstructured":"Wen J, Li HZ, Ji ZG, Mao QZ, Shi BB, Yan WG. A decade of clinical experience with extra-adrenal paragangliomas of retroperitoneum: report of 67 cases and a literature review. Urol Ann. 2010;2(1):12\u20136. https:\/\/doi.org\/10.4103\/0974-7796.62919.","journal-title":"Urol Ann"},{"issue":"4","key":"1021_CR5","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/1096-9098(200008)74:4<286::aid-jso9>3.0.co;2-c","volume":"74","author":"P Somasundar","year":"2000","unstructured":"Somasundar P, Krouse R, Hostetter R, Vaughan R, Covey T. Paragangliomas--a decade of clinical experience. J Surg Oncol. 2000;74(4):286\u201390. https:\/\/doi.org\/10.1002\/1096-9098(200008)74:4<286::aid-jso9>3.0.co;2-c.","journal-title":"J Surg Oncol"},{"issue":"6","key":"1021_CR6","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1056\/NEJMra1806651","volume":"381","author":"HPH Neumann","year":"2019","unstructured":"Neumann HPH, Young WF Jr, Eng C. Pheochromocytoma and Paraganglioma. N Engl J Med. 2019;381(6):552\u201365. https:\/\/doi.org\/10.1056\/NEJMra1806651A comprehensive review of PPGLs and genetic basis for these tumors.","journal-title":"N Engl J Med"},{"issue":"5","key":"1021_CR7","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-16-0033","volume":"174","author":"PF Plouin","year":"2016","unstructured":"Plouin PF, Amar L, Dekkers OM, Fassnacht M, Gimenez-Roqueplo AP, Lenders JW, et al. European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. Eur J Endocrinol. 2016;174(5):G1\u2013G10. https:\/\/doi.org\/10.1530\/EJE-16-0033.","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"1021_CR8","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.soc.2015.08.006","volume":"25","author":"CM Kiernan","year":"2016","unstructured":"Kiernan CM, Solorzano CC. Pheochromocytoma and paraganglioma: diagnosis, genetics, and treatment. Surg Oncol Clin N Am. 2016;25(1):119\u201338. https:\/\/doi.org\/10.1016\/j.soc.2015.08.006.","journal-title":"Surg Oncol Clin N Am"},{"issue":"12","key":"1021_CR9","doi-asserted-by":"publisher","first-page":"e68","DOI":"10.1158\/1078-0432.CCR-17-0547","volume":"23","author":"SP Rednam","year":"2017","unstructured":"Rednam SP, Erez A, Druker H, Janeway KA, Kamihara J, Kohlmann WK, et al. Von Hippel-Lindau and hereditary pheochromocytoma\/paraganglioma syndromes: clinical features, genetics, and surveillance recommendations in childhood. Clin Cancer Res. 2017;23(12):e68\u201375. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0547.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1021_CR10","doi-asserted-by":"publisher","first-page":"T91","DOI":"10.1530\/ERC-15-0268","volume":"22","author":"DE Benn","year":"2015","unstructured":"Benn DE, Robinson BG, Clifton-Bligh RJ. 15 years of paraganglioma: clinical manifestations of paraganglioma syndromes types 1-5. Endocr Relat Cancer. 2015;22(4):T91\u2013103. https:\/\/doi.org\/10.1530\/ERC-15-0268.","journal-title":"Endocr Relat Cancer"},{"issue":"19","key":"1021_CR11","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1056\/NEJMoa020152","volume":"346","author":"HP Neumann","year":"2002","unstructured":"Neumann HP, Bausch B, McWhinney SR, Bender BU, Gimm O, Franke G, et al. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med. 2002;346(19):1459\u201366. https:\/\/doi.org\/10.1056\/NEJMoa020152.","journal-title":"N Engl J Med"},{"issue":"3","key":"1021_CR12","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1136\/jmg.39.3.178","volume":"39","author":"BE Baysal","year":"2002","unstructured":"Baysal BE, Willett-Brozick JE, Lawrence EC, Drovdlic CM, Savul SA, McLeod DR, et al. Prevalence of SDHB, SDHC, and SDHD germline mutations in clinic patients with head and neck paragangliomas. J Med Genet. 2002;39(3):178\u201383.","journal-title":"J Med Genet"},{"issue":"11","key":"1021_CR13","doi-asserted-by":"publisher","first-page":"4505","DOI":"10.1210\/jc.2006-0423","volume":"91","author":"FM Brouwers","year":"2006","unstructured":"Brouwers FM, Eisenhofer G, Tao JJ, Kant JA, Adams KT, Linehan WM, et al. High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. J Clin Endocrinol Metab. 2006;91(11):4505\u20139. https:\/\/doi.org\/10.1210\/jc.2006-0423.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1021_CR14","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.beem.2006.07.005","volume":"20","author":"DE Benn","year":"2006","unstructured":"Benn DE, Robinson BG. Genetic basis of phaeochromocytoma and paraganglioma. Best Pract Res Clin Endocrinol Metab. 2006;20(3):435\u201350. https:\/\/doi.org\/10.1016\/j.beem.2006.07.005.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"1","key":"1021_CR15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/humu.21136","volume":"31","author":"CJ Ricketts","year":"2010","unstructured":"Ricketts CJ, Forman JR, Rattenberry E, Bradshaw N, Lalloo F, Izatt L, et al. Tumor risks and genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD. Hum Mutat. 2010;31(1):41\u201351. https:\/\/doi.org\/10.1002\/humu.21136.","journal-title":"Hum Mutat"},{"issue":"6","key":"1021_CR16","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1210\/jcem.83.6.4870","volume":"83","author":"G Eisenhofer","year":"1998","unstructured":"Eisenhofer G, Keiser H, Friberg P, Mezey E, Huynh TT, Hiremagalur B, et al. Plasma metanephrines are markers of pheochromocytoma produced by catechol-O-methyltransferase within tumors. J Clin Endocrinol Metab. 1998;83(6):2175\u201385. https:\/\/doi.org\/10.1210\/jcem.83.6.4870.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1021_CR17","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1093\/oxfordjournals.aje.a113947","volume":"120","author":"P Manu","year":"1984","unstructured":"Manu P, Runge LA. Biochemical screening for pheochromocytoma. Superiority of urinary metanephrines measurements. Am J Epidemiol. 1984;120(5):788\u201390.","journal-title":"Am J Epidemiol"},{"issue":"2","key":"1021_CR18","doi-asserted-by":"publisher","first-page":"101","DOI":"10.7326\/0003-4819-123-2-199507150-00004","volume":"123","author":"JW Lenders","year":"1995","unstructured":"Lenders JW, Keiser HR, Goldstein DS, Willemsen JJ, Friberg P, Jacobs MC, et al. Plasma metanephrines in the diagnosis of pheochromocytoma. Ann Intern Med. 1995;123(2):101\u20139.","journal-title":"Ann Intern Med"},{"issue":"24","key":"1021_CR19","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1056\/NEJM199906173402404","volume":"340","author":"G Eisenhofer","year":"1999","unstructured":"Eisenhofer G, Lenders JW, Linehan WM, Walther MM, Goldstein DS, Keiser HR. Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. N Engl J Med. 1999;340(24):1872\u20139. https:\/\/doi.org\/10.1056\/NEJM199906173402404.","journal-title":"N Engl J Med"},{"issue":"2","key":"1021_CR20","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1373\/clinchem.2006.076489","volume":"53","author":"JW Lenders","year":"2007","unstructured":"Lenders JW, Willemsen JJ, Eisenhofer G, Ross HA, Pacak K, Timmers HJ, et al. Is supine rest necessary before blood sampling for plasma metanephrines? Clin Chem. 2007;53(2):352\u20134. https:\/\/doi.org\/10.1373\/clinchem.2006.076489.","journal-title":"Clin Chem"},{"issue":"6","key":"1021_CR21","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1097\/MPA.0b013e3181ebb4f0","volume":"39","author":"H Chen","year":"2010","unstructured":"Chen H, Sippel RS, O\u2019Dorisio MS, Vinik AI, Lloyd RV, Pacak K, et al. The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas. 2010;39(6):775\u201383. https:\/\/doi.org\/10.1097\/MPA.0b013e3181ebb4f0.","journal-title":"Pancreas."},{"issue":"6","key":"1021_CR22","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1210\/jc.2002-030005","volume":"88","author":"G Eisenhofer","year":"2003","unstructured":"Eisenhofer G, Goldstein DS, Walther MM, Friberg P, Lenders JW, Keiser HR, et al. Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. J Clin Endocrinol Metab. 2003;88(6):2656\u201366. https:\/\/doi.org\/10.1210\/jc.2002-030005.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1021_CR23","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1055\/s-0032-1327395","volume":"138","author":"R Darr","year":"2013","unstructured":"Darr R, Lenders JW, Stange K, Kindel B, Hofbauer LC, Bornstein SR, et al. Diagnosis of pheochromocytoma and paraganglioma: the clonidine suppression test in patients with borderline elevations of plasma free normetanephrine. Dtsch Med Wochenschr. 2013;138(3):76\u201381. https:\/\/doi.org\/10.1055\/s-0032-1327395.","journal-title":"Dtsch Med Wochenschr"},{"issue":"7","key":"1021_CR24","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1097\/00006231-200607000-00006","volume":"27","author":"F Lumachi","year":"2006","unstructured":"Lumachi F, Tregnaghi A, Zucchetta P, Cristina Marzola M, Cecchin D, Grassetto G, et al. Sensitivity and positive predictive value of CT, MRI and 123I-MIBG scintigraphy in localizing pheochromocytomas: a prospective study. Nucl Med Commun. 2006;27(7):583\u20137.","journal-title":"Nucl Med Commun"},{"issue":"2","key":"1021_CR25","first-page":"173","volume":"34","author":"S Maurea","year":"1993","unstructured":"Maurea S, Cuocolo A, Reynolds JC, Tumeh SS, Begley MG, Linehan WM, et al. Iodine-131-metaiodobenzylguanidine scintigraphy in preoperative and postoperative evaluation of paragangliomas: comparison with CT and MRI. J Nucl Med. 1993;34(2):173\u20139.","journal-title":"J Nucl Med"},{"key":"1021_CR26","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1102\/1470-7330.2012.0016","volume":"12","author":"JC Baez","year":"2012","unstructured":"Baez JC, Jagannathan JP, Krajewski K, O\u2019Regan K, Zukotynski K, Kulke M, et al. Pheochromocytoma and paraganglioma: imaging characteristics. Cancer Imaging. 2012;12:153\u201362. https:\/\/doi.org\/10.1102\/1470-7330.2012.0016.","journal-title":"Cancer Imaging"},{"issue":"2","key":"1021_CR27","doi-asserted-by":"publisher","first-page":"370","DOI":"10.2214\/AJR.12.9126","volume":"200","author":"K Leung","year":"2013","unstructured":"Leung K, Stamm M, Raja A, Low G. Pheochromocytoma: the range of appearances on ultrasound, CT, MRI, and functional imaging. AJR Am J Roentgenol. 2013;200(2):370\u20138. https:\/\/doi.org\/10.2214\/AJR.12.9126.","journal-title":"AJR Am J Roentgenol"},{"issue":"9","key":"1021_CR28","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.2967\/jnumed.108.058701","volume":"50","author":"GA Wiseman","year":"2009","unstructured":"Wiseman GA, Pacak K, O\u2019Dorisio MS, Neumann DR, Waxman AD, Mankoff DA, et al. Usefulness of 123I-MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma: results from a prospective multicenter trial. J Nucl Med. 2009;50(9):1448\u201354. https:\/\/doi.org\/10.2967\/jnumed.108.058701.","journal-title":"J Nucl Med"},{"issue":"3","key":"1021_CR29","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1046\/j.1442-2042.1999.06310.x","volume":"6","author":"N Furuta","year":"1999","unstructured":"Furuta N, Kiyota H, Yoshigoe F, Hasegawa N, Ohishi Y. Diagnosis of pheochromocytoma using [123I]-compared with [131I]-metaiodobenzylguanidine scintigraphy. Int J Urol. 1999;6(3):119\u201324.","journal-title":"Int J Urol"},{"issue":"7","key":"1021_CR30","first-page":"1138","volume":"35","author":"PD Mozley","year":"1994","unstructured":"Mozley PD, Kim CK, Mohsin J, Jatlow A, Gosfield E 3rd, Alavi A. The efficacy of iodine-123-MIBG as a screening test for pheochromocytoma. J Nucl Med. 1994;35(7):1138\u201344.","journal-title":"J Nucl Med"},{"issue":"8","key":"1021_CR31","first-page":"290","volume":"64","author":"AN van der Horst-Schrivers","year":"2006","unstructured":"van der Horst-Schrivers AN, Kerstens MN, Wolffenbuttel BH. Preoperative pharmacological management of phaeochromocytoma. Neth J Med. 2006;64(8):290\u20135.","journal-title":"Neth J Med"},{"issue":"12","key":"1021_CR32","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1007\/s00259-010-1545-7","volume":"37","author":"E Bombardieri","year":"2010","unstructured":"Bombardieri E, Giammarile F, Aktolun C, Baum RP, Bischof Delaloye A, Maffioli L, et al. 131I\/123I-metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging. 2010;37(12):2436\u201346. https:\/\/doi.org\/10.1007\/s00259-010-1545-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"1021_CR33","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1093\/jnci\/djs188","volume":"104","author":"HJ Timmers","year":"2012","unstructured":"Timmers HJ, Chen CC, Carrasquillo JA, Whatley M, Ling A, Eisenhofer G, et al. Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography. J Natl Cancer Inst. 2012;104(9):700\u20138. https:\/\/doi.org\/10.1093\/jnci\/djs188.","journal-title":"J Natl Cancer Inst"},{"issue":"16","key":"1021_CR34","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1200\/JCO.2006.09.6297","volume":"25","author":"HJ Timmers","year":"2007","unstructured":"Timmers HJ, Kozupa A, Chen CC, Carrasquillo JA, Ling A, Eisenhofer G, et al. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. J Clin Oncol. 2007;25(16):2262\u20139. https:\/\/doi.org\/10.1200\/JCO.2006.09.6297.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1021_CR35","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.2967\/jnumed.117.192674","volume":"58","author":"P Garrigue","year":"2017","unstructured":"Garrigue P, Bodin-Hullin A, Balasse L, Fernandez S, Essamet W, Dignat-George F, et al. The evolving role of succinate in tumor metabolism: an (18)F-FDG-based study. J Nucl Med. 2017;58(11):1749\u201355. https:\/\/doi.org\/10.2967\/jnumed.117.192674.","journal-title":"J Nucl Med"},{"issue":"1","key":"1021_CR36","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2967\/jnumed.117.193169","volume":"59","author":"N Pandit-Taskar","year":"2018","unstructured":"Pandit-Taskar N, Zanzonico P, Staton KD, Carrasquillo JA, Reidy-Lagunes D, Lyashchenko S, et al. Biodistribution and dosimetry of (18)F-meta-fluorobenzylguanidine: a first-in-human PET\/CT imaging study of patients with neuroendocrine malignancies. J Nucl Med. 2018;59(1):147\u201353. https:\/\/doi.org\/10.2967\/jnumed.117.193169.","journal-title":"J Nucl Med"},{"issue":"10","key":"1021_CR37","doi-asserted-by":"publisher","first-page":"3922","DOI":"10.1210\/jc.2009-1054","volume":"94","author":"HB Fiebrich","year":"2009","unstructured":"Fiebrich HB, Brouwers AH, Kerstens MN, Pijl ME, Kema IP, de Jong JR, et al. 6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess. J Clin Endocrinol Metab. 2009;94(10):3922\u201330. https:\/\/doi.org\/10.1210\/jc.2009-1054.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1021_CR38","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1530\/ERC-11-0243","volume":"19","author":"JS Fonte","year":"2012","unstructured":"Fonte JS, Robles JF, Chen CC, Reynolds J, Whatley M, Ling A, et al. False-negative (1)(2)(3)I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease. Endocr Relat Cancer. 2012;19(1):83\u201393. https:\/\/doi.org\/10.1530\/ERC-11-0243.","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"1021_CR39","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1148\/radiol.2222010622","volume":"222","author":"S Hoegerle","year":"2002","unstructured":"Hoegerle S, Nitzsche E, Altehoefer C, Ghanem N, Manz T, Brink I, et al. Pheochromocytomas: detection with 18F DOPA whole body PET--initial results. Radiology. 2002;222(2):507\u201312. https:\/\/doi.org\/10.1148\/radiol.2222010622.","journal-title":"Radiology."},{"issue":"10","key":"1021_CR40","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.2967\/jnumed.108.052373","volume":"49","author":"I Ilias","year":"2008","unstructured":"Ilias I, Chen CC, Carrasquillo JA, Whatley M, Ling A, Lazurova I, et al. Comparison of 6-18F-fluorodopamine PET with 123I-metaiodobenzylguanidine and 111in-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma. J Nucl Med. 2008;49(10):1613\u20139. https:\/\/doi.org\/10.2967\/jnumed.108.052373.","journal-title":"J Nucl Med"},{"issue":"12","key":"1021_CR41","doi-asserted-by":"publisher","first-page":"4757","DOI":"10.1210\/jc.2009-1248","volume":"94","author":"HJ Timmers","year":"2009","unstructured":"Timmers HJ, Chen CC, Carrasquillo JA, Whatley M, Ling A, Havekes B, et al. Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. 2009;94(12):4757\u201367. https:\/\/doi.org\/10.1210\/jc.2009-1248.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1021_CR42","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1365-2265.2008.03496.x","volume":"71","author":"HJ Timmers","year":"2009","unstructured":"Timmers HJ, Eisenhofer G, Carrasquillo JA, Chen CC, Whatley M, Ling A, et al. Use of 6-[18F]-fluorodopamine positron emission tomography (PET) as first-line investigation for the diagnosis and localization of non-metastatic and metastatic phaeochromocytoma (PHEO). Clin Endocrinol. 2009;71(1):11\u20137. https:\/\/doi.org\/10.1111\/j.1365-2265.2008.03496.x.","journal-title":"Clin Endocrinol"},{"key":"1021_CR43","doi-asserted-by":"publisher","unstructured":"Vyakaranam AR, Crona J, Norl\u00e9n O, Hellman P, Sundin A. (11)C-hydroxy-ephedrine-PET\/CT in the diagnosis of pheochromocytoma and paraganglioma. Cancers (Basel). 2019;11(6). https:\/\/doi.org\/10.3390\/cancers11060847.","DOI":"10.3390\/cancers11060847"},{"key":"1021_CR44","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.clinimag.2019.04.006","volume":"56","author":"J Ivanidze","year":"2019","unstructured":"Ivanidze J, Roytman M, Sasson A, Skafida M, Fahey TJ 3rd, Osborne JR, et al. Molecular imaging and therapy of somatostatin receptor positive tumors. Clin Imaging. 2019;56:146\u201354. https:\/\/doi.org\/10.1016\/j.clinimag.2019.04.006.","journal-title":"Clin Imaging"},{"issue":"2","key":"1021_CR45","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1148\/rg.352140164","volume":"35","author":"MS Hofman","year":"2015","unstructured":"Hofman MS, Lau WF, Hicks RJ. Somatostatin receptor imaging with 68Ga DOTATATE PET\/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. Radiographics. 2015;35(2):500\u201316. https:\/\/doi.org\/10.1148\/rg.352140164.","journal-title":"Radiographics."},{"issue":"2","key":"1021_CR46","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.remn.2018.09.004","volume":"38","author":"AS Kroiss","year":"2019","unstructured":"Kroiss AS, Uprimny C, Shulkin BL, Gruber L, Frech A, Jazbec T, et al. (68)Ga-DOTATOC PET\/CT in the localization of metastatic extra-adrenal paraganglioma and pheochromocytoma compared with (18)F-DOPA PET\/CT. Rev Esp Med Nucl Imagen Mol. 2019;38(2):94\u20139. https:\/\/doi.org\/10.1016\/j.remn.2018.09.004Shows superiority of 68Ga-DOTATOC in detecting metastatic PPGLs compared to 18F-DOPA.","journal-title":"Rev Esp Med Nucl Imagen Mol"},{"issue":"Suppl 1","key":"1021_CR47","doi-asserted-by":"publisher","first-page":"S61","DOI":"10.1007\/s00259-011-1990-y","volume":"39","author":"M Naji","year":"2012","unstructured":"Naji M, A AL-N, et al. Eur J Nucl Med Mol Imaging. 2012;39(Suppl 1):S61\u20137. https:\/\/doi.org\/10.1007\/s00259-011-1990-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"1021_CR48","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s11307-010-0396-8","volume":"13","author":"M Naji","year":"2011","unstructured":"Naji M, Zhao C, Welsh SJ, Meades R, Win Z, Ferrarese A, et al. 68Ga-DOTA-TATE PET vs. 123I-MIBG in identifying malignant neural crest tumours. Mol Imaging Biol. 2011;13(4):769\u201375. https:\/\/doi.org\/10.1007\/s11307-010-0396-8.","journal-title":"Mol Imaging Biol"},{"issue":"7","key":"1021_CR49","doi-asserted-by":"publisher","first-page":"e351","DOI":"10.1097\/RLU.0000000000000775","volume":"40","author":"P Sharma","year":"2015","unstructured":"Sharma P, Mukherjee A, Karunanithi S, Naswa N, Kumar R, Ammini AC, et al. Accuracy of 68Ga DOTANOC PET\/CT imaging in patients with multiple endocrine Neoplasia syndromes. Clin Nucl Med. 2015;40(7):e351\u20136. https:\/\/doi.org\/10.1097\/RLU.0000000000000775.","journal-title":"Clin Nucl Med"},{"issue":"3","key":"1021_CR50","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1097\/MED.0000000000000476","volume":"26","author":"O Hamidi","year":"2019","unstructured":"Hamidi O. Metastatic pheochromocytoma and paraganglioma: recent advances in prognosis and management. Curr Opin Endocrinol Diabetes Obes. 2019;26(3):146\u201354. https:\/\/doi.org\/10.1097\/MED.0000000000000476.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"7","key":"1021_CR51","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1007\/s00259-015-3268-2","volume":"43","author":"A Archier","year":"2016","unstructured":"Archier A, Varoquaux A, Garrigue P, Montava M, Guerin C, Gabriel S, et al. Prospective comparison of (68)Ga-DOTATATE and (18)F-FDOPA PET\/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases. Eur J Nucl Med Mol Imaging. 2016;43(7):1248\u201357. https:\/\/doi.org\/10.1007\/s00259-015-3268-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"17","key":"1021_CR52","doi-asserted-by":"publisher","first-page":"3815","DOI":"10.1158\/1078-0432.CCR-15-1073","volume":"21","author":"MS Hofman","year":"2015","unstructured":"Hofman MS, Hicks RJ. Moving beyond \u201cLumpology\u201d: PET\/CT imaging of pheochromocytoma and paraganglioma. Clin Cancer Res. 2015;21(17):3815\u20137. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-1073.","journal-title":"Clin Cancer Res"},{"issue":"17","key":"1021_CR53","doi-asserted-by":"publisher","first-page":"3888","DOI":"10.1158\/1078-0432.CCR-14-2751","volume":"21","author":"I Janssen","year":"2015","unstructured":"Janssen I, Blanchet EM, Adams K, Chen CC, Millo CM, Herscovitch P, et al. Superiority of [68Ga]-DOTATATE PET\/CT to other functional imaging modalities in the localization of SDHB-associated metastatic pheochromocytoma and paraganglioma. Clin Cancer Res. 2015;21(17):3888\u201395. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2751.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1021_CR54","doi-asserted-by":"publisher","first-page":"186","DOI":"10.2967\/jnumed.115.161018","volume":"57","author":"I Janssen","year":"2016","unstructured":"Janssen I, Chen CC, Taieb D, Patronas NJ, Millo CM, Adams KT, et al. 68Ga-DOTATATE PET\/CT in the localization of head and neck paragangliomas compared with other functional imaging modalities and CT\/MRI. J Nucl Med. 2016;57(2):186\u201391. https:\/\/doi.org\/10.2967\/jnumed.115.161018.","journal-title":"J Nucl Med"},{"issue":"12","key":"1021_CR55","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1007\/s00259-013-2548-y","volume":"40","author":"A Kroiss","year":"2013","unstructured":"Kroiss A, Putzer D, Frech A, Decristoforo C, Uprimny C, Gasser RW, et al. A retrospective comparison between 68Ga-DOTA-TOC PET\/CT and 18F-DOPA PET\/CT in patients with extra-adrenal paraganglioma. Eur J Nucl Med Mol Imaging. 2013;40(12):1800\u20138. https:\/\/doi.org\/10.1007\/s00259-013-2548-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"1021_CR56","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s13139-015-0331-7","volume":"49","author":"TH Tan","year":"2015","unstructured":"Tan TH, Hussein Z, Saad FF, Shuaib IL. Diagnostic performance of (68)Ga-DOTATATE PET\/CT, (18)F-FDG PET\/CT and (131)I-MIBG scintigraphy in mapping metastatic pheochromocytoma and paraganglioma. Nucl Med Mol Imaging. 2015;49(2):143\u201351. https:\/\/doi.org\/10.1007\/s13139-015-0331-7.","journal-title":"Nucl Med Mol Imaging"},{"issue":"2","key":"1021_CR57","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s00441-018-2791-4","volume":"372","author":"D Taieb","year":"2018","unstructured":"Taieb D, Pacak K. Molecular imaging and theranostic approaches in pheochromocytoma and paraganglioma. Cell Tissue Res. 2018;372(2):393\u2013401. https:\/\/doi.org\/10.1007\/s00441-018-2791-4.","journal-title":"Cell Tissue Res"},{"issue":"6","key":"1021_CR58","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1245\/s10434-016-5739-5","volume":"24","author":"V Strajina","year":"2017","unstructured":"Strajina V, Dy BM, Farley DR, Richards ML, McKenzie TJ, Bible KC, et al. Surgical treatment of malignant pheochromocytoma and paraganglioma: retrospective case series. Ann Surg Oncol. 2017;24(6):1546\u201350. https:\/\/doi.org\/10.1245\/s10434-016-5739-5.","journal-title":"Ann Surg Oncol"},{"key":"1021_CR59","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1097\/SLA.0000000000002195","volume":"268","author":"A Roman-Gonzalez","year":"2017","unstructured":"Roman-Gonzalez A, Zhou S, Ayala-Ramirez M, Shen C, Waguespack SG, Habra MA, et al. Impact of surgical resection of the primary tumor on overall survival in patients with metastatic pheochromocytoma or sympathetic paraganglioma. Ann Surg. 2017;268:172\u20138. https:\/\/doi.org\/10.1097\/SLA.0000000000002195.","journal-title":"Ann Surg"},{"key":"1021_CR60","unstructured":"Administration UFaD. FDA approves iobenguane I 131 for rare adrenal gland tumors. 2018. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-iobenguane-i-131-rare-adrenal-gland-tumors. 2020."},{"issue":"2","key":"1021_CR61","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of (177)Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1607427Demonstrates efficacy of 177Lu-DOTATATE in midgut neuroendocrine tumors.","journal-title":"N Engl J Med"},{"issue":"4","key":"1021_CR62","first-page":"334","volume":"52","author":"F Forrer","year":"2008","unstructured":"Forrer F, Riedweg I, Maecke HR, Mueller-Brand J. Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma. Q J Nucl Med Mol Imaging. 2008;52(4):334\u201340.","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"6","key":"1021_CR63","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.surg.2006.07.030","volume":"140","author":"A Frilling","year":"2006","unstructured":"Frilling A, Weber F, Saner F, Bockisch A, Hofmann M, Mueller-Brand J, et al. Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors. Surgery. 2006;140(6):968\u201376; discussion 76-7. https:\/\/doi.org\/10.1016\/j.surg.2006.07.030.","journal-title":"Surgery."},{"issue":"10","key":"1021_CR64","first-page":"1599","volume":"47","author":"M van Essen","year":"2006","unstructured":"van Essen M, Krenning EP, Kooij PP, Bakker WH, Feelders RA, de Herder WW, et al. Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma. J Nucl Med. 2006;47(10):1599\u2013606.","journal-title":"J Nucl Med"},{"issue":"17","key":"1021_CR65","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1200\/JCO.2010.33.7873","volume":"29","author":"A Imhof","year":"2011","unstructured":"Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol. 2011;29(17):2416\u201323. https:\/\/doi.org\/10.1200\/JCO.2010.33.7873.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1021_CR66","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1055\/s-0032-1311637","volume":"44","author":"S Zovato","year":"2012","unstructured":"Zovato S, Kumanova A, Dematte S, Sansovini M, Bodei L, Di Sarra D, et al. Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE in individuals with neck or mediastinal paraganglioma (PGL). Horm Metab Res. 2012;44(5):411\u20134. https:\/\/doi.org\/10.1055\/s-0032-1311637.","journal-title":"Horm Metab Res"}],"container-title":["Current Urology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-020-01021-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11934-020-01021-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-020-01021-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T07:55:32Z","timestamp":1617263732000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11934-020-01021-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":66,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["1021"],"URL":"https:\/\/doi.org\/10.1007\/s11934-020-01021-x","relation":{},"ISSN":["1527-2737","1534-6285"],"issn-type":[{"type":"print","value":"1527-2737"},{"type":"electronic","value":"1534-6285"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"16 November 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dr. Becker has nothing to disclose. Dr. Beninato reports grant from National Cancer Institute, during the conduct of the study. Dr. Laird reports grant from National Cancer Institute, during the conduct of the study. Dr. Patel reports grants from National Cancer Institute, during the conduct of the study. Dr. Singer reports grants from Astellas\/Medivation and grants from National Cancer Institute, during the conduct of the study. Dr. Srivastava reports grants from National Cancer Institute, during the conduct of the study. EAS receives research support from Astellas\/Medivation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"2"}}